The therapeutic programme provider has now raised $9m after completing a series B round that also included Sandbox Industries and existing investor .406 Ventures.

Alder, which is developing antibodies to fight migraine and arthritis, secured $38m in a 2012 venture round backed by Novo and TPG, and will use the money from the initial public offering to forward testing.

The aldehyde disease specialist, in which Johnson & Johnson owns a 44.5% stake, could potentially raise up to $27.6m from the initial public offering.

Biogen Idec also has the option to acquire the Massachusetts-based startup, which is developing a treatment for neurologic diseases.

Kaiser Permanente-backed Agile plans to use the proceeds from its initial public offering to support clinical trials of its lead product candidate, a weekly contraceptive patch.

US-based cardiovascular drug developer Celladon has raised $50.6m in their initial public offering selling 6.325 million shares at $8 each.

Cleveland Clinic-backed healthcare services analytics provider Castlight Health has closed a $204.24m initial public offering

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, has completed a $55m series D financing. The investor syndicate was led by Novo A/S and included new investors RA Capital, Adage Capital, Sofinnova Ventures ,and an undisclosed institutional investor. The company has raised $103m to date.

Aquinox Pharmaceuticals, a Canada clinical-stage pharmaceutical company discovering and developing novel oral drug candidates to treat inflammation and cancer, has listed on Nasdaq as part of an initial public offering. Corporate venturing investors include Johnson & Johnson and Pfizer. The net proceeds of the IPO were about $47m.